Tesamorelin’s internal-fat measurements
The trials concern excess visceral fat in adults with HIV. Their measurements are specific, and so is the approved use.
The scan result
The 2014 JAMA trial enrolled 50 adults with HIV taking antiretroviral treatment. Over 6 months, tesamorelin produced a visceral-fat treatment effect of -42 cm² compared with placebo, and liver fat also fell. That comparison concerns an area of internal abdominal fat. It leaves a different question from total body weight.
The experiment is persuasive because its population, anatomical compartment and placebo comparison are explicit. A smaller belly-fat area is a meaningful finding to discuss on those terms. It becomes less informative when “belly fat” is allowed to stand for every weight concern in every population.
Tesamorelin received FDA approval in November 2010 to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. The LiverTox account describes that approved indication. General weight loss, anti-aging and non-HIV liver-fat uses remain outside that approval.
Fat returned after discontinuation
The stopping result deserves equal room. In the 52-week programme, the study groups included 273 adults assigned tesamorelin and 137 assigned placebo. Visceral fat fell 18% over 52 weeks with treatment, and reaccumulated after discontinuation. Changes in glucose measures over 52 weeks were not clinically significant.
Durability affects how much enthusiasm I can muster for a reduction. The return of visceral fat within weeks after stopping makes duration a practical part of this research, alongside the initial fall. It also leaves long-term safety relevant to any claim built around a maintained effect.
A 2026 meta-analysis combined five randomized trials in HIV-associated lipodystrophy. It found reductions in visceral, trunk and liver fat, with increased lean body mass and no serious adverse events reported. Lean body mass includes water, organs and bone as well as muscle. Counting that whole lean-mass change as new muscle would overstate the finding.
Pituitary stimulation
Tesamorelin is a 44-amino-acid analogue of growth hormone-releasing hormone, also known as TH9507. A modification at one end makes it resist an enzyme that would otherwise break the natural hormone down quickly. The clinical form is an acetate salt.
It prompts the pituitary gland beneath the brain to release growth hormone in bursts. Growth hormone then raises the liver-produced growth factor IGF-1. This stimulates the body’s own hormone system, with effects on fat metabolism, rather than supplying whole growth hormone.
The brief mechanistic trial in 13 healthy men used 2 mg/day for 2 weeks. Growth hormone increased and IGF-1 rose by 181 micrograms per litre; fasting glucose and insulin-stimulated glucose uptake were not significantly affected. Those precise observations are useful, although the brief study leaves long-term safety unanswered.
Glucose and malignancy
Raising a growth factor brings safety questions into the same discussion as the fat result. The research reports no excess malignancy signal over 52 weeks, while longer-term cancer safety remains uncertain. Active cancer is a labelled contraindication. Modest glucose changes can occur, particularly where glucose control is already impaired; prediabetes and other glucose problems make monitoring relevant to clinical care.
The LiverTox safety assessment judged tesamorelin an unlikely cause of clinically apparent liver injury, with no attributable cases reported and no new serum-enzyme elevations in trials. That narrower liver assessment cannot resolve the growth-factor or glucose questions.
WADA prohibits tesamorelin during and outside competition. Research-grade material lacks the pharmaceutical oversight of the approved prescription medicine and is not approved for self-administration. The AOD-9604 result concerns failed obesity trials, while MOTS-c has yet to establish human treatment benefit. The successful tesamorelin trials remain tied to the HIV-related condition they tested.